These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33040281)

  • 41. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
    Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent trends and future directions for the medical treatment of ulcerative colitis.
    Naganuma M; Mizuno S; Nanki K; Sugimoto S; Kanai T
    Clin J Gastroenterol; 2016 Dec; 9(6):329-336. PubMed ID: 27699641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
    Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis.
    Rosen MJ; Minar P; Vinks AA
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1094-103. PubMed ID: 25809869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
    N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
    J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
    Parikh A; Fox I; Leach T; Xu J; Scholz C; Patella M; Feagan BG
    Inflamm Bowel Dis; 2013 Jul; 19(8):1691-9. PubMed ID: 23591599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Feagan BG; Patel H; Colombel JF; Rubin DT; James A; Mody R; Lasch K
    Aliment Pharmacol Ther; 2017 Jan; 45(2):264-275. PubMed ID: 27859410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report.
    Kakiuchi T; Yoshiura M
    Medicine (Baltimore); 2022 Nov; 101(45):e31757. PubMed ID: 36397383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
    Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
    Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
    Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
    J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
    Conrad MA; Stein RE; Maxwell EC; Albenberg L; Baldassano RN; Dawany N; Grossman AB; Mamula P; Piccoli DA; Kelsen JR
    Inflamm Bowel Dis; 2016 Oct; 22(10):2425-31. PubMed ID: 27598742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
    Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
    Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.